AIM IMMUNOTECH INC.
Last · NYSE$0.2276-0.0024 (-1.04%)stale · yahoo · 245h ago
Market cap$6.93M30.4M sh
P/E · TTM-0.3fwd -0.6 · eps -0.71 · loss
Beta1.19vs S&P 500
Div yield—annual · TTM
52w range
$0.19$2.89
Volume8.5Msession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-27
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Current Ratio Low
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 68.2%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -15861.4%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -12451.1%
- Cash Runway Low — Cash runway ~0.3 years
- Current Ratio Low — Current ratio 0.53
- Rd Intensity High — R&D/Revenue 4459.1%
Press & signals
- GlobeNewswire
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
- GlobeNewswire
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
- GlobeNewswire
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags